Pharmatest offers full-service efficacy testing of new drug candidates for treatment of osteoporosis and osteoarthritis. Our osteoporosis models include in vitro bone cell cultures (osteoclasts and osteoblasts) and animal models of primary and secondary osteoporosis. The bone cell cultures can be conveniently used for identifying compounds with best efficacy for subsequent testing in animal studies.
With the osteoporosis animal models Pharmatest offers specially designed study setups for testing anti-catabolic and anabolic compounds in prevention and treatment settings. Our projects can range from preliminary studies to regulatory studies performed according to the guidelines of FDA and EMA. We have also designed special project types for testing biosimilars and functional foods that have less extensive regulatory requirements.
Our ovariectomy (OVX) and orchidectomy (ORX) models are ideal choices for the efficacy testing of anti-catabolic and anabolic compounds for postmenopausal and male osteoporosis, respectively. We also offer a model of glucocorticoid-induced osteoporosis (GIO) as a model of secondary osteoporosis.
Our rat and rabbit osteoarthritis models can be used for the efficacy testing of new compounds, including disease-modifying osteoarthritis drugs (DMOADs), for treatment of osteoarthritis. We also have a model osteogenesis imperfecta (OI).